Seeing Is Believing
Currently out of the existing stock ratings of Rachel Vatnsdal, 3 are a SELL (16.67%), 7 are a HOLD (38.89%), 8 are a BUY (44.44%).
Analyst Rachel Vatnsdal works at JPMORGAN with a stock forecast success ratio of 58.33% fulfilled within 56.57 days on average.
Rachel Vatnsdal’s has documented 44 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on PACB, Pacific Biosciences of California at 21-Apr-2024.
Analyst best performing recommendations are on MYGN (MYRIAD GENETICS).
The best stock recommendation documented was for MYGN (MYRIAD GENETICS) at 8/7/2023. The price target of $17 was fulfilled within 2 days with a profit of $0.47 (2.69%) receiving and performance score of 13.45.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
0.65
$0.51 (364.29%)
3.35
11 months 13 days ago
2/2 (100%)
$0.06 (10.17%)
10
Buy
1.25
$1.2 (2400.00%)
19
11 months 21 days ago
3/4 (75%)
$2.13 (47.39%)
21
Buy
5
$4.86 (3471.43%)
30
1 years 1 months 15 days ago
7/10 (70%)
$3.68 (278.79%)
819
Hold
2
$1.86 (1328.57%)
2.5
1 years 3 months 28 days ago
1/2 (50%)
$0.55 (37.93%)
2
Hold
1 years 5 months 22 days ago
1/2 (50%)
$7.57 (43.43%)
391
Which stock is Rachel Vatnsdal is most bullish on?
Which stock is Rachel Vatnsdal is most reserved on?
What Year was the first public recommendation made by Rachel Vatnsdal?